Clinical Trial

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer. All men in this study are being treated with hormone therapy (also called androgen deprivation therapy, or ADT). Some may also be taking newer hormone medicines such as apalutamide, daralutamide, enzalutamide, or abiraterone.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-01 -> 2029-01 2026-08-12
minor Completion pushed: 2029-01 -> 2030-01 2026-08-12
Trial Details
NCT Number NCT07224009
Lead Sponsor University of Arkansas
Conditions Metastatic Prostate Cancer
Enrollment 60 participants
Start Date 2026-08
Primary Completion 2029-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-11